Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies
Journal of Clinical Medicine · 12.03.2026 · 15 (6) · 2166
DOI: 10.3390/jcm15062166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.03.2026. Verfasst von Fabio Perrotta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Via Leonardo Bianchi, 80131 Naples, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) comprises a heterogeneous group of fibrosing lung disorders frequently complicated by progressive pulmonary fibrosis, a phenotype associated with accelerated lung function decline and increased mortality. Although antifibrotic therapies have improved clinical outcomes, significant unmet needs remain, particularly regarding treatment tolerability and integration with background immunosuppressive strategies. Preferential phosphodiesterase-4B (PDE4B) inhibition has emerged as a novel therapeutic approach targeting both inflammatory and fibrotic pathways through modulation of intracellular cyclic adenosine monophosphate signaling. This narrative review summarizes the biological rationale and emerging clinical evidence supporting nerandomilast, an oral preferential PDE4B inhibitor, in autoimmune-associated interstitial lung diseases. Preclinical data indicate that PDE4B inhibition may attenuate fibroblast activation, inflammatory signaling, and extracellular matrix deposition. Clinical trials conducted in progressive pulmonary fibrosis populations have demonstrated a reduction in lung function decline, with subgroup analyses suggesting potential benefit in autoimmune-related diseases, although evidence remains limited. The safety profile appears mainly characterized by gastrointestinal adverse events, with ongoing evaluation of neuropsychiatric safety and drug interactions in complex autoimmune populations. Overall, nerandomilast represents a promising investigational strategy bridging antifibrotic and immunomodulatory mechanisms, warranting further dedicated studies in SARD-ILD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Via Leonardo Bianchi, 80131 Naples, Italy.
- Clinic of Respiratory Diseases "Luigi Vanvitelli", A.O. dei Colli, Monaldi Hospital, 80131 Naples, Italy.
- Department of Internal Medicine and Medical Therapeutics, Medical School, University of Pavia, 27100 Pavia, Italy.
- CEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80131 Naples, Italy.
- Rheumatology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
ORCID-Profile: Domenica Francesca Mariniello, Raffaella Pagliaro, Filippo Scialò, Giulio Forte, Francesco Ciccia, Andrea Bianco
Zitieren
APA
Perrotta, F., Mariniello, D. F., Stella, G. M., Pagliaro, R., Scialò, F., Liakouli, V., Forte, G., Ciccia, F., Bianco, A., & D'Agnano, V. (2026). Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies. Journal of Clinical Medicine, 15(6), 2166. https://doi.org/10.3390/jcm15062166
Vancouver
Perrotta F, Mariniello DF, Stella GM, Pagliaro R, Scialò F, Liakouli V, et al. Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies. Journal of Clinical Medicine. 2026;15(6):2166. doi:10.3390/jcm15062166
BibTeX
@article{Perrotta2026,
author = {Perrotta, Fabio and Mariniello, Domenica Francesca and Stella, Giulia M and Pagliaro, Raffaella and Scialò, Filippo and Liakouli, Vasiliki and Forte, Giulio and Ciccia, Francesco and Bianco, Andrea and D'Agnano, Vito},
title = {Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2166},
doi = {10.3390/jcm15062166}
}
EUVIMED